Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-14

Study Completion Date

2020-07-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

NCT03288493

Multiple Myeloma

TERMINATED PHASE1/PHASE2

Study of Tremelimumab in Patients With Advanced Solid Tumors

NCT02527434

Urothelial Bladder Cancer Triple-negative Breast Cancer Pancreatic Ductal Adenocarcinoma

COMPLETED PHASE2

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03287908

Relapsed/Refractory Multiple Myeloma

TERMINATED PHASE1

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NCT01470131

Multiple Myeloma

TERMINATED PHASE3

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

NCT02592551

Mesothelioma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to characterize the safety, feasibility, and clinical activity of BPX-701, a genetically modified autologous T cell product incorporating an HLA-A2-restricted PRAME-directed TCR and a rimiducid-inducible safety switch, when administered to subjects with relapsed AML, previously treated MDS, or metastatic uveal melanoma.

The study will be comprised of multiple parts:

Part 1 (Phase 1): Cell dose escalation to identify the maximum dose of BPX-701 T cells (escalating doses from 1.25 x 10E6 cells/kg up to 5.0 x 10E6 cells/kg to be explored) Parts 2 and 3 (Phase 2): Dose expansion to assess the safety, pharmacodynamics (including BPX-701 T cell persistence and response to rimiducid as applicable), and clinical activity at the recommended dose identified in Part 1 During Parts 1, 2, or 3, rimiducid may be administered following BPX-701 T cell infusion in response to uncontrollable, treatment-emergent toxicity

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia Myelodysplastic Syndrome Uveal Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open Label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1 Does Escalation

Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.

Rimiducid may be administered in response to treatment-related toxicity.

Group Type EXPERIMENTAL

BPX-701

Intervention Type BIOLOGICAL

autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Rimiducid

Intervention Type DRUG

dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Arm 2 Dose Escalation

Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.

Rimiducid may be administered in response to treatment-related toxicity.

Group Type EXPERIMENTAL

BPX-701

Intervention Type BIOLOGICAL

autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Rimiducid

Intervention Type DRUG

dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Arm 1 Part 2 Dose Expansion

Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701 at the recommended cell dose level.

Rimiducid may be administered in response to treatment-related toxicity.

Group Type EXPERIMENTAL

BPX-701

Intervention Type BIOLOGICAL

autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Rimiducid

Intervention Type DRUG

dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Arm 2 Part 2 Dose Expansion

Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701 at the recommended cell dose level.

Rimiducid may be administered in response to treatment-related toxicity.

Group Type EXPERIMENTAL

BPX-701

Intervention Type BIOLOGICAL

autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Rimiducid

Intervention Type DRUG

dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BPX-701

autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

Intervention Type BIOLOGICAL

Rimiducid

dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AP1903

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent
2. Participants in Arm 1:

MDS not responding to hypomethylation therapy or recurrence after initial response AML with disease relapse following first complete remission with intermediate or adverse genetics according to the European Leukemia Net criteria. AML participants with prior stem cell transplant must be \>100 days post-transplant with no evidence of active graft-versus-host disease and not requiring systemic immunomodulatory or immunosuppressive therapy (\>10mg prednisone daily or treatment with a calcineurin inhibitor)
3. Participants in Arm 2:

Metastatic uveal melanoma with a radiographically measurable tumor, absolute neutrophil count \>/=1000/uL, and platelets \>/=75,000/uL
4. HLA-A2.01 positive by local testing
5. Tumor with positive PRAME expression by central testing
6. Age \>/= 18 years
7. Participant has a life expectancy \>12 weeks and is able to carry out daily life activities without difficulty (Eastern Cooperative Oncology Group performance status 0 or 1).
8. Participant has adequate venous access for apheresis or agrees to use of a central line for blood collection.
9. Participant does not have significant side effects from previous anticancer treatment.
10. Adequate organ function including absolute lymphocyte count \>/=200/uL.
11. Sexually active participants must use medically acceptable methods of contraception for at least 1 year after study treatment.

Exclusion Criteria

1. Participants with AML must not have:

* Acute promyelocytic leukemia,
* Primary refractory disease,
* Uncontrolled disseminated intravascular coagulation,
* Signs or symptoms of cancer cells in the brain or nervous system,
* Peripheral blast count \>/=20,000/uL
2. Participants with uveal melanoma must not have an untreated brain tumor
3. Participant has a history of major surgery or treatment with other cancer therapy within 2-4 weeks (1 week for hydroxyurea) before study treatment.
4. Participant has an active, autoimmune disease that requires immunosuppressive therapy. Exceptions are vitiligo, type I diabetes, certain cases of hypothyroidism and psoriasis, or Hashimoto's thyroiditis on a stable dose of thyroid replacement therapy
5. History of clinically significant heart problems.
6. Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics within 2 weeks before study treatment.
7. Participant is currently pregnant or breastfeeding.
8. Participant requires chronic, systemic steroid therapy.
9. Participant is positive for Hepatitis B, Hepatitis C, HIV, syphilis, West Nile virus, or Chagas disease.
10. Participant has side effects from earlier cancer treatment that have not resolved

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No